Frankfurt
17.04.25
08:08 Uhr
23,600 Euro
-0,600
-2,48 %
-2,48 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Ipsen's liver disease drug Iqirvo off to promising launch in battle with Gilead's Livdelzi | 5 | FiercePharma | ||
| Mi | Ipsen S.A. reports Q1 results | 1 | Seeking Alpha | ||
| Mi | Ipsen posts 11.7% Q1 sales growth, maintains 2025 guidance amid pipeline progress | 2 | Investing.com | ||
| Mi | Ipsen Pharma: Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance | 786 | GlobeNewswire (Europe) | Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission... ► Artikel lesen | |
| Mo | Ipsen Pharma: Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital | 1 | GlobeNewswire (USA) | ||
| 08.04. | Ipsen Pharma: Ipsen publishes its 2024 Universal Registration Document | 1 | GlobeNewswire (USA) | ||
| 08.04. | Ipsen's Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis | 1 | PMLiVE | ||
| 02.04. | Deutsche Bank raises Ipsen SA stock rating to buy, PT to EUR122 | 5 | Investing.com | ||
| IPSEN SA ADR Aktie jetzt für 0€ handeln | |||||
| 19.03. | Ipsen Pharma: Ipsen announces issuance of €500 million inaugural Rated Public Bond | 572 | GlobeNewswire (Europe) | Transaction follows Investment Grade ratings assignment from both S&P and Moody's
PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company... ► Artikel lesen | |
| 12.03. | Ipsen Pharma: Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins | 490 | GlobeNewswire (Europe) | PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective... ► Artikel lesen | |
| 06.03. | Ipsen Pharma: Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital | 3 | GlobeNewswire (USA) | ||
| 21.02. | Ipsen Pharma: Ipsen S.A. publishes its 2024 consolidated financial statements | 2 | GlobeNewswire (USA) | ||
| 13.02. | Ipsen targets 5%+ sales growth and 30%+ margin for 2025 amid strong pipeline and launches | 5 | Seeking Alpha | ||
| 13.02. | Ipsen-Aktie fällt nach gemischten Ergebnissen im vierten Quartal | 7 | Investing.com Deutsch | ||
| 13.02. | Ipsen stock falls following mixed Q4 results | 3 | Investing.com | ||
| 13.02. | Ipsen Full-year Revenue Rises | 1 | RTTNews | ||
| 13.02. | Ipsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook | 3 | Seeking Alpha | ||
| 13.02. | Ipsen Pharma: Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025 | 456 | GlobeNewswire (Europe) | FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2%... ► Artikel lesen | |
| 12.02. | Morgan Stanley cuts Ipsen stock rating to underweight, target to EUR120 | 2 | Investing.com | ||
| 06.02. | Ipsen Pharma: Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
IPSEN SA ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -2,48 % bei einem Aktienkurs von 23,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IPSEN SA ADR finden Sie auf Wallstreet Online.
